Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus
ACS Chemical Biology · 2023-03-17 · 18 (3) · 629-642
DOI: 10.1021/acschembio.2c00934 ↗At a glance
Journal article in ACS Chemical Biology, published online on 2023-02-28. Written by Eric Bryan and 8 co-authors. Institution: Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, United States. Major MEDLINE topics: Methicillin-Resistant Staphylococcus aureus, Prodrugs, Staphylococcal Infections. Cited 21 times so far (Crossref); 48 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, Osaka University, Takeda Science Foundation.
Abstract (original language)
Methicillin-resistant Staphylococcus aureus (MRSA) is a multidrug-resistant (MDR) bacterial pathogen of acute clinical significance. Resistance to current standard-of-care antibiotics, such as vancomycin and linezolid, among nosocomial and community-acquired MRSA clinical isolates is on the rise. This threat to global public health highlights the need to develop new antibiotics for the treatment of MRSA infections. Here, we describe a new benzamide FtsZ inhibitor (TXH9179) with superior antistaphylococcal activity relative to earlier-generation benzamides like PC190723 and TXA707. TXH9179 was found to be 4-fold more potent than TXA707 against a library of 55 methicillin-sensitive S. aureus (MSSA) and MRSA clinical isolates, including MRSA isolates resistant to vancomycin and linezolid. TXH9179 was also associated with a lower frequency of resistance relative to TXA707 in all but one of the MSSA and MRSA isolates examined, with the observed resistance being due to mutations in the ftsZ gene. TXH9179 induced changes in MRSA cell morphology, cell division, and FtsZ localization are fully consistent with its actions as a FtsZ inhibitor. Crystallographic studies demonstrate the direct interaction of TXH9179 with S. aureus FtsZ (SaFtsZ), while delineating the key molecular contacts that drive complex formation. TXH9179 was not associated with any mammalian cytotoxicity, even at a concentration 10-fold greater than that producing antistaphylococcal activity. In serum, the carboxamide prodrug of TXH9179 (TXH1033) is rapidly hydrolyzed to TXH9179 by serum acetylcholinesterases. Significantly, both intravenously and orally administered TXH1033 exhibited enhanced in vivo efficacy relative to the carboxamide prodrug of TXA707 (TXA709) in treating a mouse model of systemic (peritonitis) MRSA infection. Viewed as a whole, our results highlight TXH9179 as a promising new benzamide FtsZ inhibitor worthy of further development.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, United States.
- Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, 160 Frelinghuysen Road, Piscataway, New Jersey 08854, United States.
- TAXIS Pharmaceuticals, Inc., 9 Deer Park Drive, Suite J-15, Monmouth Junction, New Jersey 08852, United States.
- Department of Applied Chemistry, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
- Department of Biotechnology, College of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Shiga 525-8577, Japan.
ORCID profiles: Edgar Ferrer-González, Junso Fujita, Hiroyoshi Matsumura, Daniel S Pilch
Funding
- NIAID NIH HHS
- Osaka University
- Takeda Science Foundation
- National Institute of Allergy and Infectious Diseases
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan
Cite
APA
Bryan, E., Ferrer-González, E., Sagong, H. Y., Fujita, J., Mark, L., Kaul, M., LaVoie, E. J., Matsumura, H., & Pilch, D. S. (2023). Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus. ACS Chemical Biology, 18(3), 629-642. https://doi.org/10.1021/acschembio.2c00934
Vancouver
Bryan E, Ferrer-González E, Sagong HY, Fujita J, Mark L, Kaul M, et al. Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus. ACS Chemical Biology. 2023;18(3):629-642. doi:10.1021/acschembio.2c00934
BibTeX
@article{Bryan2023,
author = {Bryan, Eric and Ferrer-González, Edgar and Sagong, Hye Yeon and Fujita, Junso and Mark, Lilly and Kaul, Malvika and LaVoie, Edmond J and Matsumura, Hiroyoshi and Pilch, Daniel S},
title = {Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus},
journal = {ACS Chemical Biology},
year = {2023},
volume = {18},
number = {3},
pages = {629--642},
doi = {10.1021/acschembio.2c00934}
}
EUVIMED